Table 2.
Neuroimaging findings of study population regarding anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody seroprevalence
| Radiological findings |
Group
|
P | ||
|---|---|---|---|---|
| Positive MOG (n = 12) | Negative MOG (n = 59) | All patients (n = 72) | ||
| Brain MRI at onset | ||||
| Normal | 7 (58.3) | 23 (39.0) | 30 (42.3) | 0.216 |
| Abnormal | 5 (41.7) | 36 (61.0) | 41 (57.7) | |
| Spine MRI at onset | ||||
| Cervical | 3 (25.0) | 43 (72.9) | 46 (64.8) | 0.005* |
| Thoracic-lumbar | 4 (33.3) | 9 (15.3) | 13 (18.3) | |
| Cervical-thoracic | 5 (41.7) | 7 (11.9) | 12 (16.9) | |
| MRI at follow-up | ||||
| Increase | 0 (0) | 10 (16.9) | 10 (14.1) | 0.204 |
| No change | 2 (16.7) | 7 (11.9) | 9 (12.7) | |
| Decrease | 10 (83.3) | 35 (59.3) | 45 (63.4) | |
| Normal | 0 (0) | 7 (11.9) | 7 (9.9) | |
Data are presented as number (percent)
MOG: Myelin oligodendrocyte glycoprotein; MRI: Magnetic resonance imaging
*
Regardless of spinal cord involvement region, a significant difference was observed in comparison between seropositive and seronegative subgroups